This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Autosomal Recessive Polycystic Kidney Disease (ARPKD)상염색체열성 다낭성 신장병 (상염색체열성 다낭성신장병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q61.1 (autosomal recessive polycystic kidney disease) | Special Copayment Reduction: V264
B. SynonymsPolycystic kidney, autosomal recessive | Polycystic kidney, infantile type
C. Adult onsetLikelihood of first onset in adulthood: very low — ARPKD is a disease that presents mainly in the neonatal, infant, and childhood periods. Severe cases are detected in the fetal period (oligohydramnios, kidney overdistension) or die in the neonatal period from respiratory failure or renal failure. Milder phenotypes present at school age or in adolescence, but a first diagnosis in adulthood is extremely rare.
1. History1902 Osathanondh and Potter classification → 1971 refinement of the Potter classification → 2002 identification of the PKHD1 gene → advances in research on fibrocystin function.
2. CausesPathogenic variants in the PKHD1 gene (6p12.3-p12.2); loss of fibrocystin (fibrocystin/polyductin) function; autosomal recessive inheritance.
3. GeneticsPKHD1: 67 exons, 4,074-amino-acid fibrocystin; simple heterozygous carriers are unaffected; carrier frequency 1/70; 25% risk of being affected when both parents are carriers.
4. General epidemiology1 in 20,000 births; occurs in all ethnic groups; high neonatal mortality (severe cases); ESRD by age 10 in about 50% of surviving children.
5. PathophysiologyFibrocystin deficiency → cystic dilatation of renal collecting ducts + intrahepatic bile duct dysplasia (congenital hepatic fibrosis) → portal hypertension.
6. SymptomsNeonates: bilateral kidney overdistension, respiratory failure, renal failure. Children and adolescents: hypertension, renal failure, portal hypertension (esophageal varices, splenomegaly), cholangitis.
7. SignsBilateral nephromegaly, hypertension, proteinuria, anemia, hepatomegaly, splenomegaly, esophageal varices; increased renal echogenicity on ultrasound.
8. ScreeningPrenatal ultrasound (increased renal echogenicity, oligohydramnios); prenatal genetic diagnosis when there is a family history.
9. DiagnosisAbdominal ultrasound, PKHD1 genetic testing (confirmation), MRI, kidney biopsy (rarely); liver biopsy (evaluation of hepatic fibrosis).
10. TreatmentConservative (management of hypertension and renal failure); renal replacement therapy (dialysis, transplantation); liver transplantation or combined kidney-liver transplantation; management of portal hypertension.
11. PrognosisAbout 80% of neonatal survivors survive to adulthood; about 50% reach end-stage renal disease in childhood; hepatic fibrosis is resolved after liver transplantation.
12. PreventionGenetic counseling, preimplantation genetic testing (PGT); prenatal diagnosis; slowing progression with early treatment of hypertension and renal failure.
13. ReferencesWard CJ et al., Nat Genet 2002; Gunay-Aygun M, Pediatr Nephrol 2009, and 8 other references

1. History

Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a hereditary ciliopathy characterized by cystic dilatation of the renal collecting ducts and intrahepatic bile duct dysplasia (congenital hepatic fibrosis). The history of this disease parallels the development of classification systems for polycystic kidney disease. In 1902, Osathanondh and Potter (Edith Potter) described the polycystic kidneys found in neonates pathoanatomically, and in 1971 Potter classified cystic kidney diseases into types I~IV. Of these, Potter type I (collecting duct type) corresponds to present-day ARPKD, and the characteristic finding of microcysts involving radially arranged collecting ducts was described.

With advances in genetics in the late 20th century, the clinical and genetic differences between ARPKD and autosomal dominant polycystic kidney disease (ADPKD) were clearly established. In 1994, linkage analysis confirmed that the causative gene locus of ARPKD is located on the short arm of chromosome 6 (6p12-p21). In 2002, the research team of Ward et al. identified the PKHD1 (Polycystic Kidney and Hepatic Disease 1) gene and revealed that its product, fibrocystin (or polyductin), is a membrane protein located in the primary cilia of renal collecting duct and intrahepatic bile duct epithelial cells. This discovery was an important turning point in understanding ARPKD as one of the ciliopathies.

Since the 2000s, as research on the relationship between ciliary function and cystic kidney disease became active, it was revealed that fibrocystin regulates several cell signaling pathways, including intraciliary mTOR signaling, cAMP signaling, and Wnt signaling. On this basis, mTOR inhibitors (sirolimus, everolimus) and a V2 vasopressin receptor antagonist (tolvaptan) showed inhibition of cyst growth in ARPKD animal models, but clinical application is still limited. In Korea, ARPKD is registered and managed under the rare disease special copayment reduction code V264, and multidisciplinary treatment centered on pediatric nephrology is provided. Kidney transplantation and combined kidney-liver transplantation are performed as standard treatment in end-stage patients.

Recently, understanding of genotype-phenotype correlations in patients with ARPKD has deepened. Numerous cohort studies have confirmed that a severe phenotype is more common with two truncating variants, and a mild phenotype is more common with one or more missense variants. However, phenotypic differences can be large even within families carrying the same variants, so prognosis cannot be fully predicted from genotype alone.

2. Causes

ARPKD is an autosomal recessive genetic disease caused by pathogenic variants in both alleles of the PKHD1 (Polycystic Kidney and Hepatic Disease 1) gene, located on the short arm of chromosome 6 (6p12.3-p12.2). The PKHD1 gene is one of the largest genes in the human genome, consisting of at least 67 exons, and various splicing isoforms exist. The longest transcript produces an mRNA of about 16 kb and encodes fibrocystin (or polyductin) of 4,074 amino acids.

Fibrocystin is a single-pass transmembrane protein expressed mainly in the primary cilia and basal bodies of renal collecting duct epithelial cells and intrahepatic bile duct epithelial cells. The primary cilium is an antenna structure on the cell surface that senses mechanical and chemical stimuli and regulates various intracellular signal transduction; in renal epithelial cells it plays a key role in sensing intratubular flow and regulating signaling pathways such as mTOR, cAMP, Hedgehog, and Wnt. When fibrocystin function is lost due to PKHD1 variants, this cilia-based signal regulation is impaired, causing abnormal proliferation and cystic dilatation of collecting duct cells.

To date, more than 1,000 pathogenic variants have been reported in PKHD1, including various types such as missense variants, nonsense variants, splicing variants, and small deletions/insertions. Carrying single truncating variants (e.g., nonsense, frameshift) on both alleles tends to be associated with a severe phenotype, and carrying at least one missense variant with a mild phenotype. However, differences in phenotypic severity are observed even between siblings with the same combination of PKHD1 variants, so other genetic modifiers (modifier genes) or environmental factors are presumed to influence the phenotype.

Because ARPKD is inherited in an autosomal recessive manner, heterozygous carriers show a normal phenotype. The carrier frequency in the general population is estimated at about 1/70. When both parents are carriers, each pregnancy has a 25% probability of being affected, a 50% probability of being a carrier, and a 25% probability of being neither affected nor a carrier.

3. Genetics

The causative gene of ARPKD, PKHD1, is located on the short arm of chromosome 6 (6p12.3-p12.2) and is a large gene spanning about 470 kb of genomic length. At least 67 exons have been identified, and multiple transcripts are produced by alternative splicing. The longest transcript (NM_138694) includes all 67 exons and encodes the complete fibrocystin of 4,074 amino acids. In addition, shorter isoforms containing some of the exons exist, and tissue distribution and function may differ by isoform.

Fibrocystin consists of an extracellular N-terminal domain, a single transmembrane domain, and a short C-terminal cytoplasmic domain. The extracellular domain contains IPT (immunoglobulin-like fold shared by plexins and transcription factors) domains and TIG (transcription factor immunoglobulin) domains, presumed to be involved in cell adhesion and ligand binding. The C-terminal cytoplasmic domain interacts with polycystin-2 (PC2, important in ADPKD), 14-3-3 proteins, HDAC, and others to regulate cilia-based signal transduction.

The spectrum of PKHD1 variants is very broad, and to date more than 1,000 pathogenic variants have been reported in patients with ARPKD. The most common single variant is p.Thr36Met (c.107C>T), which shows a carrier frequency of about 20% in patients of European descent. Truncating variants (nonsense, frameshift, splicing variants) completely abolish fibrocystin and are associated with a severe phenotype. Missense variants show variable phenotypes depending on residual protein function. Phenotypic variability within the same family is being studied as involving, in addition to genotype, epigenetic variation and polymorphisms of modifier genes regulating ciliary function (e.g., DZIP1L, IFT protein genes).

Next-generation sequencing (NGS)-based gene panels or whole exome analysis are currently the standard genetic testing methods for confirming ARPKD. Because PKHD1 is very large and its variants are widely dispersed, MLPA or long-read sequencing is used as an adjunct to detect large structural variants or deep intronic variants. Molecular genetic confirmation is essential for genetic counseling, preimplantation and prenatal diagnosis, and carrier testing within families. For carrier couples, it is possible to select out affected embryos before implantation through preimplantation genetic testing (PGT).

4. General epidemiology

The prevalence of ARPKD is reported as about 1 in 20,000 births, and some studies give a range of 1 in 10,000~40,000. The carrier frequency is estimated at about 1/70 and may be higher in genetically isolated populations. ARPKD occurs in all ethnic groups and regions worldwide, and no tendency to predominate in particular ethnic groups has been established. There is also no sex difference.

The clinical spectrum of ARPKD is very diverse. In the most severe perinatal lethal form, both kidneys are extremely enlarged from the fetal period, compressing lung development, and after birth neonatal mortality is high due to respiratory failure from pulmonary hypoplasia and renal failure. Neonatal mortality is reported at 30~50% depending on the literature. Patients who survive the neonatal period progress in childhood and adolescence to complications of hypertension, renal failure, and congenital hepatic fibrosis-portal hypertension.

In surviving patients with ARPKD, the time to reach end-stage renal disease (ESRD) varies by phenotype. About 50% of all surviving ARPKD patients reach ESRD by age 10, and about 30% maintain renal function into adulthood. Hepatic complications (congenital hepatic fibrosis, portal hypertension, cholangitis) independently become serious problems even in patients with well-preserved renal function. In Korea, ARPKD is registered under the rare disease special copayment reduction code V264, and although the exact number of patients in Korea has not been published, it is estimated at a few hundred.

As large cohort studies of the natural history of ARPKD, the ARPKD/PKHD1 database conducted in North America (since 2004) and the European ARegPKD registry (since 2012) provide important epidemiological data. In these studies, the 1-year survival rate of neonatal survivors was reported as 85~90%, and the median time to kidney transplantation as about 20~30 years. Hepatic complications (especially cholangitis and portal hypertension) were confirmed as major causes of morbidity and mortality even in adulthood.

5. Pathophysiology

The core pathophysiology of ARPKD is loss of fibrocystin function due to PKHD1 gene variants, causing simultaneous cystic dilatation of the renal collecting ducts and intrahepatic bile duct dysplasia (congenital hepatic fibrosis). Fibrocystin is located in the primary cilia and basal bodies of renal collecting duct cells and intrahepatic bile duct cells and regulates various cell signaling pathways.

Mechanism of renal cystic dilatation: fibrocystin normally senses intratubular flow through the primary cilium, inhibiting mTOR (mammalian target of rapamycin) and cAMP signaling and suppressing excessive proliferation of collecting duct epithelial cells. When fibrocystin is lost, cAMP increases in collecting duct epithelial cells and the mTOR pathway is overactivated, promoting cell proliferation. At the same time, cAMP activates CFTR (cystic fibrosis transmembrane conductance regulator) or other chloride channels in collecting duct cells, so chloride and water are secreted into the cyst and the cyst expands. As a result, the renal collecting ducts become uniformly cystically dilated throughout, and the kidneys become massive. In ARPKD, unlike ADPKD, the cysts are characteristically microcysts (1~2 mm in size) distributed radially throughout the collecting ducts.

Pathophysiology of Congenital Hepatic Fibrosis (CHF): fibrocystin is also expressed in the epithelial cells of the intrahepatic bile ducts (especially small bile ducts and interlobular bile ducts). Loss of fibrocystin causes dysplasia of the intrahepatic bile duct epithelium (ductal plate malformation, DPM), so the bile ducts proliferate abnormally and become embedded in fibrotic stroma. This bile duct dysplasia causes extensive fibrosis around the portal vein (pericentric fibrosis), resulting in congenital hepatic fibrosis. The hepatic parenchyma is relatively preserved, but fibrosis around the portal vein increases resistance to portal blood flow and causes portal hypertension. As a result of portal hypertension, splenomegaly, esophageal and gastric varices, gastrointestinal bleeding, and ascites develop. When bile stagnates in the abnormal bile ducts, the risk of bacterial infection (cholangitis) increases.

Impaired lung development: when severely enlarged kidneys compress the diaphragm and occupy abdominal space in the fetal period, they physically interfere with lung development. In addition, when amniotic fluid production decreases due to reduced renal function (oligohydramnios), expansion and maturation of the fetal lungs are impaired, resulting in pulmonary hypoplasia, which is the main cause of neonatal death.

6. Symptoms

The clinical symptoms of ARPKD vary greatly depending on the time of onset (perinatal, neonatal, childhood, adolescence) and the degree of renal and hepatic involvement.

Perinatal and neonatal symptoms: in the severe phenotype, prenatal ultrasound shows markedly enlarged kidneys bilaterally (several times normal) and oligohydramnios. It is accompanied by the Potter sequence—characteristic facial deformities due to oligohydramnios (flattened nose, ear malformations), limb contractures, and pulmonary hypoplasia. After birth, respiratory failure due to pulmonary hypoplasia is an immediate life-threatening factor and the main cause of neonatal death. Renal failure (oliguria, electrolyte abnormalities) occurs at the same time. Abdominal distension is severe and both kidneys are palpable.

Childhood and adolescent symptoms: in patients who survive the neonatal period, the following symptoms gradually appear. Hypertension is the most common symptom, caused by activation of the renin-angiotensin-aldosterone system (RAAS), and appears from early childhood. Renal failure progresses with a decrease in glomerular filtration rate (GFR) and is accompanied by growth failure, anemia, and electrolyte abnormalities. Symptoms of portal hypertension—splenomegaly, bleeding from esophageal and gastric varices (hematemesis, melena), ascites—appear as hepatic fibrosis progresses. Cholangitis results from bacterial infection within the abnormal bile ducts and is characterized by fever, right upper quadrant pain, and jaundice. Nocturia, polyuria, and pyuria may also appear.

Mild phenotype: some patients pass through the neonatal period asymptomatically and are first diagnosed at school age or in adolescence with hypertension, proteinuria, hematuria, or abdominal discomfort. In these cases, renal function is relatively preserved and hepatic complications are more prominent.

7. Signs

The following physical and laboratory findings are identified.

Abdominal findings: due to bilateral nephromegaly, the kidneys are palpable as firm masses on both sides of the abdomen. Hepatomegaly and splenomegaly accompany. In severe cases, abdominal distension due to ascites is observed. In neonates, both kidneys are enlarged to the point of occupying most of the abdominal cavity.

Blood pressure: hypertension appears from early childhood and often progresses to refractory hypertension that is difficult to treat. Systolic hypertension may be observed even in neonates and infants.

Growth retardation: growth velocity decreases due to chronic renal failure, hypertension, and malnutrition. Responsiveness to growth hormone may also be reduced.

Laboratory findings: elevated serum creatinine, decreased GFR (indicator of renal failure), serum electrolyte abnormalities (hyperkalemia, metabolic acidosis), anemia (renal anemia), proteinuria, and hematuria appear. On liver function tests, elevated alkaline phosphatase and GGT suggest congenital hepatic fibrosis. Thrombocytopenia reflects hypersplenism. Elevated serum ammonia is observed in advanced hepatic fibrosis or portal hypertension.

Imaging findings: abdominal ultrasound shows markedly enlarged kidneys bilaterally with increased echogenicity (appearing bright) and loss of corticomedullary differentiation. Microcysts are not seen as individual cysts on ultrasound but appear as a pattern of increased echogenicity. MRI is useful for accurately measuring the characteristics and distribution of cysts and kidney volume and for evaluating hepatic fibrosis.

8. Screening

General population screening for ARPKD is not performed. The main screening situations are as follows.

Prenatal ultrasound screening: ARPKD is suspected when bilaterally increased renal echogenicity (hyperechoic), nephromegaly, and oligohydramnios are observed on detailed ultrasound during pregnancy (18~22 weeks of gestation). Prenatal diagnosis before symptom onset in the neonatal period helps with delivery planning and preparation for neonatal intensive care. However, the mild phenotype shows no abnormality on prenatal ultrasound, making diagnosis difficult.

When there is a family history: a couple with a child with ARPKD has a 25% risk of an affected child in the next pregnancy. If the PKHD1 variants of a previously affected child have been identified, whether the next child is affected can be determined by preimplantation genetic testing (PGT) or prenatal genetic testing (chorionic villus sampling, amniocentesis). When the PKHD1 variants in the family are known, carrier testing of siblings is also recommended.

Situations of clinical suspicion: when a child has bilateral nephromegaly of unknown cause, refractory hypertension, proteinuria, hepatomegaly, or splenomegaly, ARPKD is included in the differential diagnosis and abdominal ultrasound and PKHD1 genetic testing are performed.

9. Diagnosis

Diagnosis of ARPKD is made through clinical and imaging findings and genetic testing.

Abdominal ultrasound: in neonates and children, uniformly increased echogenicity of both kidneys, nephromegaly, and loss of corticomedullary differentiation are characteristic. On liver ultrasound, increased hepatic echogenicity, hepatic fibrosis, or intrahepatic bile duct dilatation may be observed. Splenomegaly and ascites are also checked.

Abdominal MRI: precisely evaluates total kidney volume (TKV), the distribution of microcysts, hepatic fibrosis (increased liver volume, portal vein dilatation), and spleen size without radiation. In ARPKD, the kidneys show a characteristic striated or sponge pattern on MRI because the microcysts are uniformly distributed.

PKHD1 genetic testing: confirmation is possible when pathogenic variants in both alleles are identified by an NGS-based gene panel (including a cystic kidney disease panel) or PKHD1 sequencing alone. The positivity rate of genetic testing is about 80~85%, and in the remaining 15~20% variants may not be identified (deep intronic variants, large structural variants, etc.). Even if no variant is found, a clinical diagnosis is possible when the clinical and imaging findings are consistent.

Kidney biopsy: radial cystic dilatation of the collecting ducts is diagnostic, but now that genetic testing is available, kidney biopsy is rarely performed. It is considered only when genetic testing is inconclusive and differential diagnosis is needed.

Liver biopsy and MRE: MR elastography (MRE) is used noninvasively to assess the degree of hepatic fibrosis. On liver biopsy, ductal plate malformation and periportal fibrosis are diagnostic, but it is now rarely performed because the diagnosis can often be made clinically and by imaging.

10. Treatment

There is as yet no treatment for ARPKD that directly corrects the underlying genetic abnormality, and treatment centers on management of complications and organ replacement therapy.

Neonatal intensive care: for respiratory failure due to pulmonary hypoplasia, ventilator support, high-frequency oscillatory ventilation, inhaled nitric oxide, and extracorporeal membrane oxygenation (ECMO) are used. When breathing is difficult due to severe nephromegaly and renal failure is severe, nephrectomy followed by peritoneal dialysis is sometimes performed. In this case, life is maintained by dialysis without kidneys, and kidney transplantation is performed after the child grows to an appropriate size.

Management of hypertension: renin-angiotensin blockers (ACE inhibitors, angiotensin receptor blockers) are used first for blood pressure control and renal protection. Calcium channel blockers, beta blockers, and diuretics are added. Strict blood pressure control is important for slowing the progression of renal failure.

Renal replacement therapy and transplantation: on reaching end-stage renal disease, peritoneal dialysis or hemodialysis is performed, followed by kidney transplantation. In Korea, living partial kidney transplantation is mainly performed. After kidney transplantation, hepatic fibrosis and portal hypertension may persist and require separate management.

Management of portal hypertension: nonselective beta blockers (propranolol) are used to prevent esophageal variceal bleeding. In variceal bleeding, endoscopic variceal ligation (EVL) or sclerotherapy is performed. Ascites is managed with diuretics and a low-salt diet, and for refractory ascites, TIPS (transjugular intrahepatic portosystemic shunt) or paracentesis is used. When portal hypertension is severe and liver function is impaired, liver transplantation or combined kidney-liver transplantation is considered.

Prevention and treatment of cholangitis: for cholangitis resulting from bacterial infection of the abnormal bile ducts, prophylactic antibiotics (trimethoprim-sulfamethoxazole) are sometimes used, and when cholangitis occurs, it is treated immediately with broad-spectrum antibiotics.

Research on inhibition of renal cyst growth: the V2 receptor antagonist tolvaptan has been FDA-approved for ADPKD, but clinical studies in ARPKD are in progress. mTOR inhibitors (sirolimus, everolimus) were also effective in animal models, but clinical study results are mixed. Somatostatin analogs (lanreotide, octreotide) are also under study.

11. Prognosis

The prognosis of ARPKD varies greatly depending on survival of the neonatal period, the severity of pulmonary hypoplasia, the rate of renal function decline, and the progression of hepatic complications.

Neonatal mortality: the main cause of neonatal death is respiratory failure due to pulmonary hypoplasia; mortality has been decreasing with advances in neonatal intensive care but is still high at about 30~50%. The 1-year survival rate of neonatal survivors is 85~90%.

Long-term renal prognosis: of neonatal survivors, about 50% reach ESRD by age 10, and about 30% maintain native renal function until age 20. The 5-year survival rate after kidney transplantation is good at 90% or more.

Prognosis of hepatic complications: in patients whose renal function is relatively preserved, portal hypertension, cholangitis, and progressive hepatic fibrosis become major causes of morbidity and mortality. After liver transplantation or combined kidney-liver transplantation, hepatic fibrosis and portal hypertension improve, and the 5~10-year survival rate after transplantation is 85~90%.

Follow-up: regular assessment of renal function (eGFR, urinalysis), blood pressure, kidney and liver ultrasound or MRI, liver function tests, endoscopy (surveillance for esophageal varices), and growth and development is needed. Ongoing management at a multidisciplinary clinic specializing in ARPKD is recommended.

12. Prevention

Primary prevention of ARPKD is achieved through genetic counseling and preimplantation and prenatal genetic testing. When PKHD1 variants have been identified in a couple with a previously affected child, affected embryos are selected out before implantation by PGT, or the status is confirmed by prenatal genetic testing (chorionic villus sampling or amniocentesis). Because heterozygous carriers are normal, carrier testing and genetic counseling are key to preventing recurrence.

Secondary prevention: the severe phenotype is detected early by prenatal ultrasound, and a delivery plan (preparation for neonatal intensive care) is established in advance. Renal and lung function are evaluated immediately in the neonatal period and intensive care is started.

Tertiary prevention: strict control of hypertension, slowing the progression of renal failure (reducing proteinuria, RAAS blockade), prevention and immediate treatment of cholangitis, and early treatment of complications of portal hypertension (variceal bleeding, ascites) contribute to maintaining quality of life and improving survival. Establishing a transplant plan before renal function declines minimizes the duration of dialysis.

13. References

  1. Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet. 2002;30(3):259-269. PMID: 11919560.
  2. Gunay-Aygun M. Liver and kidney disease in ciliopathies. Am J Med Genet C Semin Med Genet. 2009;151C(4):296-306. PMID: 19876928.
  3. Bergmann C, Senderek J, Windelen E, et al. Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease. Kidney Int. 2005;67(3):829-848. PMID: 15698423.
  4. Sweeney WE Jr, Avner ED. Diagnosis and management of childhood polycystic kidney disease. Pediatr Nephrol. 2011;26(5):675-692. PMID: 20960025.
  5. Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics. 2014;134(3):e833-845. PMID: 25157014.
  6. Guay-Woodford LM, Bissler JJ, Braun MC, et al. Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2014;29(9):1617-1625. PMID: 24778020.
  7. Adeva M, El-Youssef M, Rossetti S, et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease. Medicine (Baltimore). 2006;85(1):1-21. PMID: 16523049.
  8. Turkbey B, Ocak I, Daryanani K, et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. Pediatr Radiol. 2009;39(2):100-111. PMID: 19002453.
  9. Burgmaier K, Kilian S, Bammens B, et al. Clinical courses and complications of young adults with autosomal recessive polycystic kidney disease. Sci Rep. 2019;9(1):7918. PMID: 31138829.
  10. Audrézet MP, Corbiere C, Lebbah S, et al. Comprehensive PKD1 and PKD2 mutation analysis in prenatal autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):722-729. PMID: 26376859.